Live Breaking News & Updates on Labafenogene marselecobac
Stay updated with breaking news from Labafenogene marselecobac. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Synlogic Inc. jolted Wall Street with news that the firm is scrapping for futility Synpheny-3, its pivotal study with labafenogene marselecobac (SYNB-1934) for phenylketonuria, and will evaluate strategic options. Shares of the Cambridge, Mass.-based firm (NASDAQ:SYBX) fell 48.7%, or $1.68, to end Feb. 9 at $1.77. Synlogic will cease operations and reduce its workforce by more than 90%, retaining only certain employees to help with the wind-down.